Effects of Low Phytanic Acid-Concentrated DHA on Activated Microglial Cells: Comparison with a Standard Phytanic Acid-Concentrated DHA.
Level 5 - mechanism / opinion, no new human data
In vitro bench research using a mouse microglial cell line
PubMed 29846873 · doi:10.1007/s12017-018-8496-8
What was done
Mouse microglial BV-2 cells were exposed to neurotoxic stressors (lipopolysaccharide or hydrogen peroxide) and co-incubated with either low phytanic acid DHA (50 ppm PhA) or standard phytanic acid DHA (500 ppm PhA). The investigators evaluated cell viability, superoxide anion production, and the protein expression of inflammatory, oxidative, apoptotic, and neurotrophic markers (IL-6, COX-2, iNOS, GtPx, GtRd, SOD-1, Caspase-3, and BDNF).
What was found
The abstract reports directional differences without numerical values, confidence intervals, or statistical test metrics. Compared to standard DHA (500 ppm PhA), low-PhA DHA (50 ppm PhA) preserved cell viability against neurotoxic challenge and reduced superoxide anion production. Low-PhA DHA also decreased the protein expression of COX-2, IL-6, iNOS, GtPx, GtRd, and SOD-1, while increasing BDNF protein expression.
Why it matters
Phytanic acid impurities in commercial DHA supplements may diminish DHA's anti-inflammatory and neuroprotective actions, potentially explaining some inconsistencies observed across preclinical and clinical DHA studies.
Limits
This is an in vitro experiment conducted in an immortalized mouse cell line (BV-2), which cannot replicate complex tissue architecture, in vivo metabolism, or human neurodegenerative pathology. The abstract omits sample sizes (replicate counts), concentrations used, and exact quantitative data or effect sizes.
Cited by
- supports DHA acts as a COX-2 inhibitor and directly enhances BDNF (brain-derived neurotrophic factor) production.